New hope for rare skin cancer? drug cocktail targets resistant DFSP
Disease control
Not yet recruiting
This phase 2 trial will test whether combining two newer drugs (toripalimab and anlotinib) with standard chemotherapy can shrink tumors in people with a rare skin cancer called dermatofibrosarcoma protuberans (DFSP) that has stopped responding to the usual treatment. The study pl…
Phase: PHASE2 • Sponsor: Yanjie Zhang, MD • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC